tetano
Editor, Senior Moderator
J Allergy Clin Immunol Glob
. 2023 Jun 25;2(4):100129.
doi: 10.1016/j.jacig.2023.100129. eCollection 2023 Nov. SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies
Kevin T Cao[SUP] 1 [/SUP], Catalina Cobos-Uribe[SUP] 1 [/SUP], Noelle Knight[SUP] 2 [/SUP], Rithika Jonnalagadda[SUP] 3 [/SUP], Carole Robinette[SUP] 2 [/SUP], Ilona Jaspers[SUP] 1 2 4 [/SUP], Meghan E Rebuli[SUP] 1 2 4 [/SUP]
Affiliations
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine-induced systemic antibody profiles are well characterized; however, little is known about whether intranasal mucosal antibodies are induced or can neutralize virus in response to mRNA vaccination.
Objective: We sought to evaluate intranasal mucosal antibody production with SARS-CoV-2 mRNA vaccination.
Methods: SARS-CoV-2-specific IgG and IgA concentrations and neutralization activity from sera and nasal mucosa via nasal epithelial lining fluid (NELF) collection were measured in SARS-CoV-2 mRNA-vaccinated healthy volunteers (N = 29) by using multiplex immunoassays. Data were compared before and after vaccination, between mRNA vaccine brands, and by sex.
Results: SARS-CoV-2 mRNA vaccination induced an intranasal immune response characterized by neutralizing mucosal antibodies. IgG antibodies displayed greater Spike 1 (S1) binding specificity than did IgA in serum and nasal mucosa. Nasal antibodies displayed greater neutralization activity against the receptor-binding domain than serum. Spikevax (Moderna)-vaccinated individuals displayed greater SARS-CoV-2-specific IgG and IgA antibody concentrations than did Comirnaty (BioNTech/Pfizer)-vaccinated individuals in their serum and nasal epithelial lining fluid. Sex-dependent differences in antibody response were not observed.
Conclusion: SARS-CoV-2 mRNA vaccination induces a robust systemic and intranasal antibody production with neutralizing capacity. Spikevax vaccinations elicit a greater antibody response than does Comirnaty vaccination systemically and intranasally.
Keywords: NELF; SARS-CoV-2; antibodies; antigens; epitope; mRNA vaccine; mucosal immune response; neutralization; serum; systemic immune response.
. 2023 Jun 25;2(4):100129.
doi: 10.1016/j.jacig.2023.100129. eCollection 2023 Nov. SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies
Kevin T Cao[SUP] 1 [/SUP], Catalina Cobos-Uribe[SUP] 1 [/SUP], Noelle Knight[SUP] 2 [/SUP], Rithika Jonnalagadda[SUP] 3 [/SUP], Carole Robinette[SUP] 2 [/SUP], Ilona Jaspers[SUP] 1 2 4 [/SUP], Meghan E Rebuli[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 37781659
- PMCID: PMC10290737
- DOI: 10.1016/j.jacig.2023.100129
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine-induced systemic antibody profiles are well characterized; however, little is known about whether intranasal mucosal antibodies are induced or can neutralize virus in response to mRNA vaccination.
Objective: We sought to evaluate intranasal mucosal antibody production with SARS-CoV-2 mRNA vaccination.
Methods: SARS-CoV-2-specific IgG and IgA concentrations and neutralization activity from sera and nasal mucosa via nasal epithelial lining fluid (NELF) collection were measured in SARS-CoV-2 mRNA-vaccinated healthy volunteers (N = 29) by using multiplex immunoassays. Data were compared before and after vaccination, between mRNA vaccine brands, and by sex.
Results: SARS-CoV-2 mRNA vaccination induced an intranasal immune response characterized by neutralizing mucosal antibodies. IgG antibodies displayed greater Spike 1 (S1) binding specificity than did IgA in serum and nasal mucosa. Nasal antibodies displayed greater neutralization activity against the receptor-binding domain than serum. Spikevax (Moderna)-vaccinated individuals displayed greater SARS-CoV-2-specific IgG and IgA antibody concentrations than did Comirnaty (BioNTech/Pfizer)-vaccinated individuals in their serum and nasal epithelial lining fluid. Sex-dependent differences in antibody response were not observed.
Conclusion: SARS-CoV-2 mRNA vaccination induces a robust systemic and intranasal antibody production with neutralizing capacity. Spikevax vaccinations elicit a greater antibody response than does Comirnaty vaccination systemically and intranasally.
Keywords: NELF; SARS-CoV-2; antibodies; antigens; epitope; mRNA vaccine; mucosal immune response; neutralization; serum; systemic immune response.